Emyria's response to ASX query

Emyria Limited (ASX: $EMD) has responded to ASX's query regarding the change in price and trading volume of the company's securities. The company addressed ASX's specific questions and provided explanations for the recent trading activity.

Emyria's Explanation and Response

Emyria stated that the recent increase in media attention, particularly the feature article and news story on Emyria's innovative research programs for potential treatments for post-traumatic stress disorder (PTSD), has contributed to the price and volume increase. The company highlighted its unique status as one of the few organizations in Australia approved by the Therapeutic Goods Administration (TGA) to use MDMA for therapeutic purposes. Additionally, Emyria mentioned a collaboration with Reach Wellness, a non-for-profit organization focused on delivering solutions for first responders' mental and physical health. Emyria clarified that the collaboration was progressing towards a non-binding memorandum of understanding with Reach Wellness, which has not yet been finalized, and explained the reasons for not disclosing the details of the MOU at this stage.

Summary of Emyria's Response and Outlook

Emyria's response to ASX's query provided insights into the factors contributing to the recent trading activity of its securities. The company attributed the increase to heightened media attention and the potential collaboration with Reach Wellness. Emyria emphasized its commitment to compliance with the ASX Listing Rules and confirmed that the response had been authorized and approved by the Board. Looking ahead, Emyria's innovative research programs and collaborations indicate a focus on developing treatments for PTSD, reflecting the company's strategic direction towards addressing mental health challenges. The company's outlook may be influenced by the progress of its collaboration with Reach Wellness and the potential impact of its research programs on the market.